Metastasis-Initiating Cells: Drivers of Cancer Spread and Relapse

Metastasis-initiating cells represent a distinct subpopulation of tumor cells with the unique ability to drive cancer dissemination and colonization of distant organs. These cells display stem cell–like features, including self-renewal, plasticity, and survival in hostile microenvironments, which makes them crucial players in tumor progression and therapy resistance. Because they differ from the bulk of tumor cells, their identification and characterization have become central to understanding why certain cancers relapse and spread despite treatment.

In this blog post, we will explore the biological basis of metastasis-initiating cells, their molecular markers and signaling pathways, the mechanisms through which they promote metastatic spread, their clinical relevance, and the emerging therapeutic strategies designed to target them.

2. Biological Basis of Metastasis-Initiating Cells

The emergence of metastasis-initiating cells is closely linked to the dynamic nature of tumors, which are not uniform masses of identical cells but rather heterogeneous ecosystems. Within this cellular diversity, certain subpopulations acquire traits that allow them to detach, migrate, and survive beyond the primary tumor. These specialized cells, endowed with stem cell–like properties, form the cornerstone of metastatic competence.

Tumor Heterogeneity and Cellular Plasticity

One of the defining features of cancer is tumor heterogeneity, meaning that not all cancer cells behave in the same way. While many cells in a tumor remain localized and lack invasive capacity, metastasis-initiating cells demonstrate cellular plasticity—the ability to shift between phenotypes depending on environmental cues. This flexibility provides a selective advantage during metastasis, enabling cells to adapt to varying conditions in circulation and distant tissues. Plasticity also underlies their ability to evade therapies that target more differentiated tumor cell populations.

Epithelial–Mesenchymal Transition (EMT)

The epithelial–mesenchymal transition (EMT) is a key biological process through which epithelial cancer cells lose their cell–cell adhesion properties and acquire a more motile, mesenchymal phenotype. EMT equips metastasis-initiating cells with invasive and migratory abilities necessary for intravasation and dissemination. Importantly, EMT is not a permanent state; metastasis-initiating cells can revert through mesenchymal–epithelial transition (MET) once they reach secondary sites, aiding in colonization and outgrowth. This reversible nature of EMT illustrates the remarkable adaptability of these cells.

Self-Renewal and Dormancy

Metastasis-initiating cells share critical properties with cancer stem cells, most notably self-renewal. This capacity ensures that even a small number of disseminated cells can generate a new tumor at distant sites. However, not all disseminated cells immediately proliferate. Many enter a state of dormancy, remaining viable but non-dividing for extended periods. Dormancy protects these cells from chemotherapy, which primarily targets rapidly dividing cells, and explains why metastases can emerge years after successful treatment of the primary tumor.

The Tumor Microenvironment and Stem Cell Niche

The survival and expansion of metastasis-initiating cells are not determined solely by intrinsic properties. The tumor microenvironment (TME)—composed of stromal cells, immune cells, extracellular matrix, and signaling molecules—plays a decisive role. Within both the primary tumor and metastatic sites, metastasis-initiating cells exploit specialized microenvironments known as stem cell niches. These niches provide survival signals, protect against immune surveillance, and support dormancy or activation depending on systemic cues. For example, cytokines and growth factors within the pre-metastatic niche create favorable conditions for colonization long before metastatic cells arrive.

3. Molecular Markers and Pathways

The identification of molecular markers and signaling pathways that regulate metastasis-initiating cells has become a cornerstone in understanding how these cells acquire metastatic competence. These markers not only provide insight into the biology of metastasis but also serve as potential biomarkers for diagnosis and therapeutic targets for intervention.

Surface Markers of Metastasis-Initiating Cells

Several cell surface molecules are consistently associated with metastasis-initiating cells across multiple cancer types.

• CD44: Perhaps the most widely studied, CD44 is a cell adhesion molecule involved in migration, homing, and interaction with the extracellular matrix. Its high expression is linked to enhanced metastatic potential and resistance to therapy.
• ALDH1 (Aldehyde Dehydrogenase 1): An enzyme critical for detoxification and stemness. Elevated ALDH1 activity marks a subpopulation of tumor cells with high self-renewal capacity and metastatic competence.
• CXCR4: A chemokine receptor that guides tumor cells toward distant organs expressing its ligand, CXCL12. This receptor–ligand interaction is central to organ-specific metastasis, particularly in breast and prostate cancers.
• EpCAM (Epithelial Cell Adhesion Molecule): Plays a dual role in cell adhesion and signaling. High EpCAM expression has been observed in circulating tumor cells (CTCs) and is often used for their detection in liquid biopsies.
• Integrins: These transmembrane receptors regulate cell adhesion to the extracellular matrix and are vital for invasion, survival in circulation, and colonization at distant sites.

Together, these markers provide a framework for identifying metastasis-initiating cells and are increasingly being explored as diagnostic tools.

Key Signaling Pathways in Metastatic Competence

Metastasis-initiating cells rely on the activation of several developmental and oncogenic signaling pathways to maintain their plasticity, self-renewal, and invasive potential.

• Wnt/β-Catenin Pathway: Crucial for maintaining stemness, Wnt signaling promotes proliferation and survival of metastasis-initiating cells. Dysregulation of this pathway is linked to tumor initiation and metastasis in colorectal and breast cancers.
• Notch Pathway: A regulator of cell fate and differentiation. Aberrant Notch signaling contributes to EMT induction and therapy resistance, enabling metastasis-initiating cells to persist under treatment pressure.
• Hedgehog Pathway: Essential for embryonic development, Hedgehog reactivation in cancer supports self-renewal and invasion of metastasis-initiating cells, particularly in pancreatic and prostate cancers.
• TGF-β (Transforming Growth Factor-Beta): Functions as a double-edged sword; while it suppresses tumorigenesis in early stages, in advanced tumors it drives EMT, immune evasion, and metastatic dissemination.
• PI3K/AKT Pathway: Provides survival signals to metastasis-initiating cells, enabling resistance to apoptosis and adaptation to stress conditions during circulation and colonization.

Pathway Crosstalk and Plasticity

These pathways rarely act in isolation. Instead, metastasis-initiating cells exhibit crosstalk between multiple signaling cascades. For example, TGF-β can synergize with Wnt/β-catenin to reinforce EMT, while PI3K/AKT signaling can intersect with Notch to promote therapy resistance. This interconnected network highlights the plastic nature of metastasis-initiating cells and underscores why targeting a single pathway often proves insufficient in clinical settings.

Clinical Implications

The identification of molecular markers and signaling pathways not only enhances our understanding of metastasis biology but also holds direct clinical relevance. Markers such as CD44, ALDH1, and EpCAM are already being used to detect circulating tumor cells through liquid biopsy technologies. Moreover, inhibitors targeting Wnt, Notch, Hedgehog, and PI3K/AKT pathways are under investigation as potential strategies to disrupt the survival of metastasis-initiating cells.

4. Mechanisms of Metastatic Dissemination

The spread of cancer from a primary tumor to distant organs is not a random event but a carefully orchestrated process known as the metastatic cascade. Metastasis-initiating cells are uniquely adapted to navigate this cascade, overcoming barriers that most tumor cells cannot. Their ability to migrate, survive, and colonize new environments explains why only a minority of circulating cells succeed in establishing metastases.

Local Invasion and Intravasation

The first step in metastatic dissemination is local invasion, during which metastasis-initiating cells breach the surrounding stroma. These cells remodel the extracellular matrix by secreting proteolytic enzymes such as matrix metalloproteinases (MMPs), which degrade structural barriers and open pathways for migration.

Following invasion, cells gain access to the circulatory or lymphatic system in a process known as intravasation. This step is often facilitated by interactions between metastasis-initiating cells, stromal fibroblasts, and tumor-associated macrophages, which collectively weaken endothelial barriers. Intravasation is a critical checkpoint, as only cells with enhanced motility and survival capacity can enter circulation successfully.

Survival in Circulation

The bloodstream is a hostile environment where most tumor cells perish due to shear stress, anoikis (detachment-induced apoptosis), and immune surveillance. Metastasis-initiating cells employ several strategies to survive these challenges:

• Platelet cloaking: By binding to platelets, they shield themselves from natural killer (NK) cell–mediated destruction and increase their chances of arrest in distant capillaries.
• Metabolic flexibility: They adapt to oxidative stress by switching between glycolysis and oxidative phosphorylation, maintaining energy production under fluctuating conditions.
• Dormancy signaling: Some cells enter a transient dormant state, reducing their metabolic activity and avoiding immune detection during circulation.

These adaptations explain why circulating tumor cells (CTCs) are rare but disproportionately enriched in metastasis-initiating properties.

Extravasation and Colonization

To establish metastases, cells must exit circulation through extravasation. This involves adhesion to endothelial cells via integrins and selectins, followed by transmigration into surrounding tissues.

Once extravasated, metastasis-initiating cells face the challenge of colonization—the most limiting step of the metastatic cascade. Colonization requires adaptation to the microenvironment of the secondary organ, which often differs significantly from the primary tumor site. The ability to exploit local growth factors and immune-modulatory signals determines whether disseminated tumor cells will proliferate or remain dormant.

Pre-Metastatic Niche Formation

Before colonization occurs, some tumors actively prepare distant sites through the creation of a pre-metastatic niche. Primary tumors release extracellular vesicles, cytokines, and growth factors that condition specific organs, altering stromal and immune cell populations. These changes create a hospitable environment that supports the seeding and outgrowth of metastasis-initiating cells. For instance, tumor-derived exosomes carrying integrins have been shown to direct organ-specific metastasis, effectively “guiding” cells to their target destination.

Immune Evasion and Long-Term Persistence

Even after colonization, metastasis-initiating cells must evade immune clearance to establish overt metastases. They achieve this through mechanisms such as:

• Expression of immune checkpoint molecules like PD-L1, which suppress T cell activity.
• Recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) to dampen anti-tumor immunity.
• Remodeling of the extracellular matrix to create physical barriers against immune infiltration.

These strategies allow disseminated tumor cells to persist for years, explaining late relapses observed in certain cancers.

5. Clinical Evidence and Relevance

While metastasis-initiating cells are largely defined by experimental studies, a growing body of clinical evidence supports their existence and role in cancer progression. Their detection in patient samples, correlation with poor prognosis, and association with therapeutic resistance all highlight their clinical significance.

Breast Cancer: The Paradigm of Metastasis-Initiating Cells

Breast cancer is one of the most well-studied models for metastasis-initiating cells. Subpopulations expressing CD44^high/CD24^low and ALDH1 have been consistently linked to enhanced metastatic potential. Clinical studies have demonstrated that patients with tumors enriched in these markers are more likely to develop distant metastases and relapse after treatment. Moreover, circulating tumor cells (CTCs) detected in the blood of breast cancer patients often carry these stem-like signatures, and their presence correlates with worse survival outcomes.

Colorectal Cancer: Markers of Relapse and Dissemination

In colorectal cancer, the expression of EpCAM and CD133 in CTCs has been associated with early relapse following surgical resection. Patients with detectable stem-like CTCs post-surgery exhibit a significantly higher risk of recurrence, suggesting that metastasis-initiating cells can persist even after removal of the primary tumor. Molecular profiling has also revealed activation of Wnt/β-catenin signaling in these cells, further linking stemness pathways to clinical relapse.

Pancreatic Cancer: Resistance and Aggressiveness

Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive metastatic behavior and resistance to therapy. Clinical evidence shows that cells with high CXCR4 expression preferentially migrate to the liver, the most common metastatic site in PDAC. Importantly, CXCR4-positive subpopulations are often resistant to chemotherapy, making them central to both early dissemination and therapy failure. Trials targeting the CXCR4–CXCL12 axis are ongoing, reflecting the translational importance of this pathway.

Prostate Cancer: Dormancy and Late Relapse

In prostate cancer, metastasis-initiating cells have been implicated in bone metastases, which often emerge years after primary tumor treatment. Disseminated tumor cells (DTCs) isolated from bone marrow aspirates exhibit stem-like features and can remain dormant for extended periods. Clinically, this explains why some patients experience metastatic recurrence a decade or more after prostatectomy. The ability of these cells to enter and exit dormancy represents a major challenge in managing long-term outcomes.

Clinical Biomarkers and Liquid Biopsy

The concept of liquid biopsy has brought metastasis-initiating cells into clinical practice. By isolating and characterizing CTCs from patient blood, clinicians can non-invasively monitor disease progression, detect minimal residual disease, and predict therapeutic resistance. Surface markers such as EpCAM, CD44, and ALDH1 are increasingly used in CTC detection platforms. Importantly, the molecular characterization of CTCs provides real-time insights into tumor evolution and metastatic potential.

Prognostic and Therapeutic Implications

The presence of metastasis-initiating cells in patient samples consistently correlates with poor prognosis, higher relapse rates, and reduced overall survival. Clinically, their detection could help stratify patients into high-risk groups, guiding more aggressive monitoring or adjuvant therapy. Furthermore, therapies that fail to target these cells may yield only temporary responses, as residual metastasis-initiating cells can repopulate tumors and drive recurrence.

6. Therapeutic Targeting of Metastasis-Initiating Cells

Despite advances in oncology, metastasis remains the leading cause of cancer-related mortality. A major reason is the persistence of metastasis-initiating cells, which resist conventional therapies and serve as reservoirs for relapse. Targeting these cells presents both opportunities and challenges, as their plasticity and overlap with normal stem cell biology complicate therapeutic design.

Challenges in Targeting Metastasis-Initiating Cells

Traditional treatments such as chemotherapy and radiotherapy primarily target rapidly dividing cells. However, metastasis-initiating cells often adopt a dormant or slow-cycling state, allowing them to evade these approaches. Furthermore, their ability to dynamically shift phenotypes through processes like EMT enables adaptation and survival under therapeutic pressure.

Another major challenge is the overlap of molecular pathways between metastasis-initiating cells and normal stem cells. Pathways such as Wnt, Notch, and Hedgehog are essential for normal tissue regeneration, raising concerns about off-target toxicity when designing inhibitors. As a result, therapeutic strategies must balance efficacy with preservation of normal stem cell function.

Targeting Signaling Pathways

Efforts to disrupt the signaling networks that sustain metastasis-initiating cells are underway:

• Wnt/β-catenin inhibitors: Small molecules and antibodies that block Wnt signaling are being investigated to reduce self-renewal capacity.
• Notch inhibitors: Gamma-secretase inhibitors, which block Notch receptor activation, have shown promise in preclinical models but face toxicity issues in clinical trials.
• Hedgehog pathway inhibitors: Drugs like vismodegib, approved for basal cell carcinoma, are being evaluated in pancreatic and prostate cancers where Hedgehog signaling drives metastasis.
• CXCR4 antagonists: Agents such as plerixafor are designed to block the CXCR4–CXCL12 axis, thereby preventing organ-specific homing of metastasis-initiating cells.

These approaches highlight the importance of pathway-specific interventions, though many remain in early clinical stages.

Immunotherapeutic Approaches

Immunotherapy has opened new avenues for targeting metastasis-initiating cells:

• Immune checkpoint inhibitors (ICIs): By blocking PD-1/PD-L1 or CTLA-4 signaling, ICIs may enhance immune recognition of metastasis-initiating cells that evade detection.
• Cancer vaccines: Experimental vaccines targeting tumor-specific antigens expressed on metastasis-initiating cells are under development to stimulate long-lasting immune surveillance.
• Adoptive cell therapy: Engineered T cells (CAR-T or TCR-based therapies) designed against CSC-related markers such as EpCAM or CD44 show potential to directly eradicate metastasis-initiating populations.

Harnessing the immune system offers a promising strategy, especially when combined with pathway inhibitors.

Emerging and Innovative Strategies

Beyond conventional targeting, novel strategies aim to disrupt the unique biology of metastasis-initiating cells:

• Nanomedicine: Nanoparticles can deliver drugs specifically to metastasis-initiating cells using surface marker–guided targeting, reducing systemic toxicity.
• Epigenetic therapy: Drugs that modulate chromatin structure (e.g., HDAC inhibitors, DNA methyltransferase inhibitors) may reverse stem-like traits and sensitize these cells to conventional therapies.
• Microenvironmental disruption: Therapies that modify the pre-metastatic niche, inhibit angiogenesis, or alter extracellular vesicle communication could prevent successful colonization of distant sites.
• Combination therapies: Integrating targeted agents with immunotherapy or chemotherapy may overcome resistance by attacking multiple vulnerabilities simultaneously.

Conclusion

Metastasis-initiating cells occupy a central role in the complexity of cancer progression, serving as key drivers of dissemination, colonization, and therapeutic resistance. Their unique biological traits, distinct molecular markers, and contribution to disease relapse highlight their clinical significance. While considerable progress has been made in understanding their mechanisms, translating this knowledge into effective therapies remains an ongoing challenge. Continued research into their biology, pathways, and vulnerabilities holds promise for developing targeted interventions that could significantly improve outcomes for patients with metastatic cancer.

References:

1. Massagué J, Ganesh K. Metastasis-Initiating Cells and Ecosystems. Cancer Discov. 2021 Apr;11(4):971-994. https://doi.org/10.1158/2159-8290.CD-21-0010
2. Celià-Terrassa, T., & Kang, Y. (2016). Distinctive properties of metastasis-initiating cells. Genes & Development, 30(8), 892–908. https://doi.org/10.1101/gad.277681.116
3. Fares, J., Fares, M.Y., Khachfe, H.H. et al. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther 5, 28 (2020). https://doi.org/10.1038/s41392-020-0134-x
4. Datta N, Vp S, Parvathy K, A S S, Maliekal TT. ALDH1A1 as a marker for metastasis initiating cells: A mechanistic insight. Exp Cell Res. 2024 Sep 1;442(1):114213. doi: 10.1016/j.yexcr.2024.114213.
5. Young, C.M., Beziaud, L., Dessen, P. et al. Metabolic dependencies of metastasis-initiating cells in female breast cancer. Nat Commun 14, 7076 (2023). https://doi.org/10.1038/s41467-023-42748-8
6. Seeneevassen, L., Zaafour, A., Sifré, E. et al. Targeting metastasis-initiating cancer stem cells in gastric cancer with leukaemia inhibitory factor. Cell Death Discov. 10, 120 (2024). https://doi.org/10.1038/s41420-024-01839-1
7. Mimeault M, Batra SK. New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today. 2010 May;15(9-10):354-64. doi: 10.1016/j.drudis.2010.03.009. Epub 2010 Mar 23. PMID: 20338259; PMCID: PMC2906246.
8. Wang, J.; Ford, J.C.; Mitra, A.K. Defining the Role of Metastasis-Initiating Cells in Promoting Carcinogenesis in Ovarian Cancer. Biology 2023, 12, 1492. https://doi.org/10.3390/biology12121492
9. Fico F, Bousquenaud M, Rüegg C, Santamaria-Martínez A. Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition. Stem Cell Reports. 2019 Jul 9;13(1):1-9. doi: 10.1016/j.stemcr.2019.05.026. Epub 2019 Jun 27. PMID: 31257133; PMCID: PMC6626885.
10. Aznar Benitah S. Metastatic-initiating cells and lipid metabolism. Cell Stress. 2017 Nov 21;1(3):110-114. doi: 10.15698/cst2017.12.113. PMID: 31225441; PMCID: PMC6551630
11. Wu C, Weis SM, Cheresh DA. Tumor-initiating cells establish a niche to overcome isolation stress. Trends Cell Biol. 2024 May;34(5):380-387. doi: 10.1016/j.tcb.2023.08.001. Epub 2023 Aug 26. PMID: 37640611.